Appointment of experts to support development of lead candidate VMB-100, an RNA-based therapy for Stress Urinary Incontinence Versameb AG (“Versameb”), focused on discovering and developing innovative RNA-based drugs, today announces the formation of an Advisory Board comprised of industry leaders in urology. These include Professor Roger Dmochowski of Vanderbilt University, Professor Margot Damaser of the […]
Data demonstrates first-in-class potential as a regenerative treatment of Stress Urinary Incontinence Treatment results in muscle regeneration with restored functionality in pre-clinical models Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, today announces that its Chief Scientific Officer, Friedrich Metzger will be presenting data on the Company’s mRNA […]
eTheRNA immunotherapies NV (“eTheRNA”) is pleased to announce the start of a strategic partnership with Merck with the signing of a Research Agreement. The partnership will investigate the application of eTheRNA’s proprietary mRNA design expertise and LNP-delivery platforms to disease areas selected by Merck. The ongoing pandemic has underlined the capability for mRNA vaccines as […]
VMB-100 shows therapeutic potential in Stress Urinary Incontinence RNA engineering technology enhances the potency of mRNA Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based drugs, today announces that its Chief Scientific Officer, Friedrich Metzger, will be presenting data on its mRNA engineering technology and lead therapeutic candidate, VMB-100, at […]
